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Azoxymethane (AOM) administration followed by repetitive dextran sulfate sodium (DSS) 
ingestion causes chronic colonic inflammation with macrophage infiltration and enhanced 
expression of a macrophage-tropic chemokine, CCL2, in wild-type (WT) mice. These mice 
eventually develop multiple colon tumors. In contrast, mice deficient in CCR2, a specific 
receptor for CCL2, exhibited less macrophage infiltration and attenuated tumor formation. 
WT mice transplanted with CCR2-deficient bone marrow developed fewer tumors after AOM 
and DSS treatment than either WT or CCR2-deficient mice transplanted with WT bone 
marrow. Furthermore, when injected to WT mice with multiple colon tumors, a CCL2 
antagonist expression vector attenuated macrophage and granulocyte infiltration, and 
eventually reduced the numbers and sizes of tumors. These results implied the crucial 
involvement of the CCL2-CCR2 interactions in the development and progression of colon 




Ulcerative colitis (UC) is an inflammatory bowel disease, characterized by repetitive relapses 
and remissions, which can cause epithelial dysplasia and can progress to invasive cancer. 
Thus, long-standing UC is a predisposing factor for colon cancer development. The combined 
administration of a carcinogen, azoxymethane (AOM) and dextran sulfate sodium (DSS) to 
rodents is widely employed in order to recapitulate colon cancer associated with chronic 
inflammation such as UC. DSS causes extensive mucosal inflammatory reaction in the colon, 
and a prior AOM administration accelerates development of colon carcinomas. In this 
AOM/DSS-induced colon carcinogenesis, massive intracolonic infiltration of macrophages is 
consistently observed and is presumed to have a crucial role. 
Monocyte chemoattractant protein-1 (MCP-1)/CCL2 is a chemokine which regulates the 
migration and activation of monocytes/macrophages. It exerts its effects through binding to its 
specific receptor, CCR2. Accumulating evidence indicates the role of the CCL2/CCR2 axis in 
various chronic inflammatory diseases, and in cancer pathobiology. 
To explore the role of CCL2/CCR2 axis in AOM/DSS-induced colon carcinogenesis, we used 
CCR2-deficient mice and the gene delivery of an N-terminal deletion mutant of human CCL2 
(7ND), which effectively inhibits CCL2 in vivo (1). Our experiments revealed that the 
CCL2/CCR2 interactions induced the recruitment of cyclooxygenase (COX)-2-expressing 




Pathogen-free 8- to 12-week old female wild-type BALB/c mice (WT) and CCR2-/- mice were 
injected intraperitoneally with 12 mg/kg body weight of AOM (Sigma-Aldrich, Inc., St. Louis, 
MO) dissolved in physiological saline. Five days later, 2 % DSS ((MW 36,000-50,000; MP 
Biochemicals Inc., Aurora, OH) was given in the drinking water over five days, followed by 
16 days of regular water. This cycle was repeated a total of 3 times (Fig. 1A). In another 
series of experiments, human 7ND-expressing- or pcDNA3 vector were injected into the 
femoral muscle of WT mice at day 56, followed by electroporation with an electrical pulse 
generator (ECM830; BTX, San Diego, CA) (Fig. 4A). All animal experiments were 
performed in compliance with the Guideline for the Care and Use of Laboratory Animals of 
Kanazawa University. 
 
Bone marrow chimeric mice generation 
Cell suspensions from male WT or CCR2-/- bone marrow were prepared from femurs and 
tibias. Female WT or CCR2-/- mice received a single intravenous injection of 1 x 107 bone 
marrow cells, after being irradiated with 4.25 Gy X-rays followed by 4.25 Gy X-rays 
(MPR-1520R; Hitachi) 4 hours later. The following groups of chimeric mice were generated; 
WT to WT, WT to CCR2-/-, CCR2-/- to WT, and CCR2-/- to CCR2-/- mice.  
 
Histopathological and immunohistochemical analyses of mouse colon tissues 
Paraffin-embedded or frozen sections of mouse colon were used for immunohistochemical 
dectetion of β-catenin-, CCR2-, MCP-1/CCL2-, F4/80-, Ly-6G-, COX-2-, cytokeratin 20-, 
and CD31-positive cells. Positive cells were enumerated on 5 randomly chosen visual fields at 
x 400 magnification. The pixel numbers of CD31-positive areas were measured on 5 
randomly chosen visual fields at x 200 magnification with the aid of Adobe Photoshop 
software. 
 
Quantitative RT-PCR analysis 
Real-Time PCR was performed on Applied Biosystems StepOne™ Real-Time PCR System 
using the comparative CT quantitaion method. TaqMan® Gene Expression Assays (Applied 
Biosystems, Foster City, CA), containing specific primers (accession numbers:  
MCP-1/CCL2 – Mm00441242_m1, KC/CXCL1 – Mm00433859_m1, COX-2 – 
Mm00478374_m1, GAPDH – Mm99999915_g1) and TaqMan® MGB probe (FAM ™ 
dye-labeled),  TaqMan® Fast Universal PCR Master Mix were used with 10 ng of cDNA to 
detect and quantify the expression levels of MCP-1/CCL2, KC/CXCL1, and COX-2 in mouse 
colon tissues.  
 
Statistical analysis 
The mean±S.D. were calculated for all parameters determined. Statistical significance 
was evaluated using one-way analysis of variance (ANOVA), and p values lower than 0.05 




Enhanced CCL2 expression in the colon during the course of colon carcinogenesis 
A single intraperitoneal injection of the carcinogen AOM, followed by 3 rounds of 2% DSS 
intake, induced the development of multiple tumors in the middle to distal colon of WT mice 
(Fig. 1B, C). Because we previously observed a massive infiltration of macrophages during 
the course of this colon carcinogenesis process (2), we investigated the expression of the 
macrophage-tropic chemokine MCP-1/CCL2 and its specific receptor, CCR2. CCL2 mRNA 
expression level was negligible in untreated WT mice, but DSS intake augmented it (Fig. 1D). 
CCL2 protein was detected in mononuclear cells infiltrating into lamina propria and 
submucosal regions, endothelial cells at the earlier phase and colon carcinoma cells at the 
later phase (data no shown). CCR2 was expressed by mononuclear cells infiltrating the lamina 
propria and submucosa, and in some colon carcinoma cells during the course of this colon 
carcinogenesis (data not shown). 
 
Reduction in AOM/DSS-induced inflammatory reaction and subsequent tumor 
formation in the absence of CCR2 
Consistently, microscopical analysis demonstrated that WT mice developed severe 
inflammation in the middle to distal colon at day 7. At day 14, inflammatory cell infiltration 
persisted, accompanied with dysplastic glands (data not shown). Moreover, 
immunohistochemical analysis demonstrated that inflammatory cells consisted of 
F4/80-positive macrophages and Ly6G-positive granulocytes (Fig.1E, F). At days 28 to 35, 
adenocarcinomatous lesions with nuclear β-catenin accumulation appeared in the presence of 
macrophage and granulocyte infiltration, and their sizes and numbers increased progressively, 
thereafter (Fig.1B, C). On the contrary, CCR2-/- mice displayed mild inflammatory changes in 
the colon during the course of DSS intake as evidenced by attenuated infiltration of 
macrophages and granulocytes (Fig.1E, F) and eventually developed few adenocarcinomatous 
lesions with less nuclear β-catenin accumulation (Fig. 1B, C). These observations implied the 
CCL2/CCR2 interactions as crucial for the development of chronic inflammation-associated 
colon carcinoma development. 
 
Contribution of CCR2-expressing bone marrow-derived cells to colon carcinogenesis 
Because CCR2 is expressed by non-bone marrow- as well as bone marrow-derived cells, we 
explored the contribution of CCR2-expressing non-bone marrow- and bone marrow-derived 
cells to this colon carcinogenesis by using bone marrow chimeric mice prepared between WT 
and CCR2-/- mice. Upon the combined treatment with AOM and DSS,  CCR2-/- and WT 
mice transplanted with WT mouse-derived bone marrow cells, developed tumors to similar 
but at a higher level than either WT or CCR2-/- mice transplanted with CCR2-/- mouse-derived 
bone marrow (Fig. 2). These observations would indicate that CCR2-expressing bone 
marrow-derived cells but not non-bone marrow-derived cells were mainly responsible for 
tumor development in this model. 
 
Reduction in AOM/DSS-induced expression of COX-2 in CCR2-/- mice 
Mirroring the crucial roles of COX-2 in colon carcinogenesis, COX-2 mRNA expression and 
COX-expressing cell number were increased in WT mice later than 7 days after the initiation 
of DSS treatment (Fig. 3), as we previously observed (2). AOM/DSS-induced increases in 
COX-2 mRNA expression and COX-2-positive cell numbers, were depressed in the absence 
of CCR2 (Fig. 3A, C). Collectively, AOM/DSS failed to increase the expression of COX-2 in 
CCR2-/- mice. 
 
Reduction of tumor formation by CCR2 antagonist administration 
In order to delineate the role of the CCR2/CCL2 interactions in the progression phase of this 
colon carcinogenesis model, we administered CCL2 N-terminal deleted form 
(7ND)-expression vector, a CCR2 antagonist, after the three cycles of DSS intake, when 
multiple colon tumors have developed. When WT mice were treated with 7ND-expressing 
vector, the numbers and sizes of macroscopical tumors were markedly reduced (Fig. 4B, C). 
Concomitantly, the treatment with 7ND-expressing vector decreased the numbers of 
infiltrating macrophages and neutrophils (Fig. 4D, E). Moreover, 7ND administration reduced 
intracolonic COX-2 mRNA expression and COX-2 expressing cell numbers (Fig. 4F and data 
not shown). Moreover, 7ND treatment decreased intratumoral CD31-positive vascular areas 
significantly (Fig. 4G, H). Furthermore, 7ND treatment decreased β-catenin nuclear 
accumulation in the tumor cells (Fig. 4I) and cytokeratin 20-positive cell numbers (data not 
shown). Collectively, these observations would indicate that the CCR2/CCL2 interactions 
were crucially involved even in the progression phase after multiple tumors developed, by 
regulating COX-2-expressing inflammatory cell infiltration. 
Discussion 
 
Accumulating evidence suggests that the CCL2/CCR2 axis plays important roles in the 
pathogenesis of various diseases by regulating the infiltration of macrophages. Indeed, the 
intramuscular transduction of the mutant MCP-1 gene, 7ND, MCP-1 inhibitor, inhibited 
vascular remodeling in rats (1), atherosclerosis progression in mice (3), and ameliorated renal 
ischemia-reperfusion injury and renal fibrosis in mice (4, 5). Thus, 7ND may effectively 
block CCL2/CCR2 signaling and play a protective role in related diseases.  
Chemokines contribute to tumor growth and progression and CCL2 is reported to be 
expressed by a variety of cancer types. CCL2 may exert its tumor promoting effects by 
recruiting macrophages, which are major sources of growth and angiogenic factors. Once 
secreted from colon adenoma cells, CCL2 can stimulate COX-2 expression, as well as PGE2 
and VEGF release from human macrophages (6). Simultaneously, CCL2 can exert growth 
stimulating effects on CCR2-expressing tumor cells in an autocrine manner. In addition, 
CCL2 has been reported to possess proangiogenic activity on CCR2-expressing endothelial 
cells (7).  
In this study we demonstrated that CCL2 production was enhanced during the course of 
AOM/DSS-induced colon carcinogenesis. Moreover, blocking of the CCL2/CCR2 signaling 
could attenuate colon tumorigenesis by decreasing the numbers of infiltrating 
COX-2-expressing macrophages and neutrophils, leading to reduced neovascularization and 
β-catenin activation. Thus, targeting the CCL2/CCR2 axis may prove beneficial for patients 
with inflammation-associated cancers. 
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Figure 1. Tumor formation and inflammatory cell infiltration in WT and CCR2-/- mice after 
AOM and DSS treatment. (A) Schematic overview of the experimental procedures. (B) 
Macroscopical appearance of the colons. Colons were removed at day 56 from treated WT 
and CCR2-/- mice and representative results from 10 independent animals are shown here. (C) 
Tumor numbers. Colons were removed at day 56 to determine the numbers of macroscopic 
tumors. Results are presented as mean ± SD (n=10 animals). **, p<0.01 versus WT mice. 
(D) MCP-1/CCL2 gene expression in the colons of WT mice. The levels of CCL2 mRNA 
were quantified by real-time RT-PCR as described in Methods, and normalized to the level of 
GAPDH mRNA. *, p<0.05, **, p<0.01 versus untreated (control) mice. (E, F) The numbers 
of F4/80- (E) and Ly-6G- positive (F) cells were counted as described in Methods and are 
shown here. All values represent the mean + SD (n=10 animals), *, p<0.05, **, p<0.01 vs. 
untreated (control) mice.  
 
Figure 2. Colon tumor formation in bone marrow chimeric mice. 
Bone marrow chimeric mice were generated and subjected to AOM and DSS treatment as 
described in Methods. Colons were removed at day 56 and the tumor numbers were 
determined macroscopically. The bars represent the median of each group; each symbol 
represents the tumor numbers of each animal group (n=4÷5), *, p<0.05, **, p<0.01; NS, not 
significant. 
 
Figure 3. COX-2 expression in the colons. 
(A) Quantitative RT-PCR was performed on total RNAs extracted from the colons at the 
indicated time points as described in Methods. The levels of COX-2 mRNA were normalized 
to the levels of GAPDH mRNA.*, p<0.05, **, p<0.01, vs. untreated mice. (B, C) 
Immunohistochemical detection of COX-2 expressing cells. Colons were obtained from WT 
mice at the indicated time points and immunostained with anti-COX-2 antibody as described 
in Methods. Representative results from 6 independent animals are shown in B. Original 
magnification, x 400. The numbers of COX-2 expressing cells are shown in C and expressed 
as mean±SD. *, p<0.05, **, p<0.01, vs. untreated mice.  
 
Figure 4. The effects of 7ND vector injection on colon carcinogenesis. 
(A) Schematic overview of 7ND administration. (B) The tumor numbers and sizes were 
determined macroscopically. The bars represent the median of each group. Each symbol 
represents the tumor numbers of each animal or the average size of the tumors of each animal. 
(C) Macroscopic evaluation of the tumors. Colons were removed on day 67 from WT mice, 
injected with 7ND or with empty plasmid. Representative results from 7 to 8 independent 
animals are shown here. (D) and (E) F4/80-positive macrophage (D) and Ly-6G-positive 
granulocytes (E) were enumerated as described in Methods. All values represent the mean + 
SD (n=5 animals). *, p<0.05, **, p<0.01, vs. empty plasmid injected WT mice. (F) 
Quantitative RT-PCR analysis for COX-2 was performed on total RNAs extracted from the 
colons at the indicated time points as described in Methods. The levels of COX-2 mRNA 
were normalized to those of GAPDH mRNA. **, p<0.01, vs. empty plasmid injected WT 
mice. (G, H) Colon tissues were immunostained with anti-CD31 antibody as described in 
Methods. The vascular densities were determined as described in Methods and are shown in 
G. *, p<0.05 vs. empty plasmid injected WT mice. (I) The β-catenin nuclear localization ratio 
was determined as the ratio of the numbers of tumor nuclei with β-catenin localization to the 
total number of tumor nuclei per field. At least 5 randomly chosen fields at x 400 
magnification were examined. All values represent the mean + SD, *, p<0.05, vs. empty 
plasmid injected WT mice. 




